Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eiger Biopharmaceuticals

09/04/2024 19:42

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of $49.39​​ per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of $-17.10.  The lone analyst forecast for
the quarter was for a loss of $7.50 per share. 
    * Revenue rose 41.1% to $3.80 million from a year ago;
analysts
expected $6.48 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of $49.39​.
    * The company reported a quarterly loss of $13.45 million.
    * Eiger BioPharmaceuticals Inc shares had fallen by 57.8%
this
quarter and lost 68.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $30.00 
This summary was machine generated from LSEG data April 9 at
06:42 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -7.50          -49.39         Missed
 Sep. 30 2023      -9.71          -12.30         Missed
 Jun. 30 2023      -12.30         -14.10         Missed
 Mar. 31 2023      -14.19         -15.60         Missed